Invest-NL has identified financing the first industrial plant as a central obstacle for Dutch food-biotech ingredients, including proteins made through fermentation. Its assessment, published on 30 October, calls for customers, infrastructure, regulation and public capital to be brought into the scale-up process together. Read Invest-NL's assessment.
The institution says first factories can require tens to hundreds of millions of euros, while existing support schemes can exclude companies facing years of losses. Its wider agrifood-biotech work draws on more than 150 stakeholder interviews and investment data covering 2010 to April 2026.
FoodEdge view: who carries the manufacturing risk?
For founders and investors, the useful consequence is a more demanding financing question. A successful demonstration can justify the next technical step while leaving the plant's financing unresolved. Our reading is that a funding plan needs to show who carries each remaining risk: construction, qualification, operating performance and customer adoption.
Bringing a buyer into that discussion could help define the specification and expected purchasing conditions before equipment is fixed. An expression of interest would still need to be distinguished from a binding purchase commitment. Public risk sharing could help finance a plant; it would leave the need for acceptable unit costs and repeat customers intact.
The announcement supplies a policy diagnosis rather than a new funding window. A concrete development to watch is a financing instrument with published eligibility, risk allocation and terms that a first factory could actually use. Until then, the revenue scenarios provide a reason to investigate the bottleneck, with no additional cash to put in a company's runway calculation.
Sources and reporting
Desk report on Invest-NL's 30 October announcement. The underlying scenario model was not independently audited by FoodEdge.
AI tools supported source research and drafting during the editorial process.
